CHAMPIONS ONCOLOGY, INC. (NASDAQ:CSBR) Files An 8-K Regulation FD Disclosure
Item 7.01.
Regulation FD Disclosure.
Attached as Exhibit 99.1 to this Current Report on Form 8-K is the investor presentation of Champions Oncology, Inc., which may be used in presentations to investors from time to time in the future. The information in this report shall not be treated as filed for purposes of the Securities Exchange Act of 1934, as amended.
|
Item 9.01. |
Financial Statements and Exhibits. |
(d) exhibits
The following exhibit is filed herewith:
Exhibit No.
|
99.1 |
Investor presentation materials
|
CHAMPIONS ONCOLOGY, INC. Exhibit
EX-99.1 2 irpresentation1718.htm EXHIBIT 99.1 irpresentation1718 Investor Presentation January 2019 Confidential 1 Notice of Forward Looking Statements This presentation contains certain “forward-looking statements,…
To view the full exhibit click here
About CHAMPIONS ONCOLOGY, INC. (NASDAQ:CSBR)
Champions Oncology, Inc. is engaged in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. The Company has two business segments: Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). The POS segment provides physicians and patients information to help guide the development of personalized treatment plans. The TOS segment provides services to pharmaceutical and biotechnology companies seeking personalized approaches to drug development. Its TumorGraft Technology Platform consists of processes, physical tumors and information that it uses to personalize the development and use of oncology drugs. Each tumor from patients that it has preserved for implantation in mice, along with the patient data and molecular information associated with the tumors, are known as TumorGrafts or Patient Derived XenoGrafts of PDX Models. The collection of TumorGrafts is referred to as the Company’s TumorBank.
